RespireRx Pharmaceuticals — Technical Presentation (June 2017)
9 slides from RespireRx Pharmaceuticals's technical presentation, Jun 6, 2017
Slide 1: Phase 2A Clinical Trial of Ampakine CX1739 in the Prevention of Opioid-Induced Respiratory Depression
Phase 2A Clinical Trial of Ampakine CX1739 in the Prevention of Opioid- Induced Respiratory Depression WN RespireRx Pharmaceuticals Inc Antagonism of Remifentani|-induced Respiratory Depression by CX1739 in Two Clinical Models of Opioid Induced Respiratory Depression (OIRD) Andrew Krystal, MD'®, Joh
Slide 2: Overall Study Design: CX1739 vs. Placebo in Combination with the Opioid Remifentanil
Overall Study Design: CX1739 vs. Placebo in Combination with the Opioid Remifentanil STAGE 1 STAGE 2 Double-blind, Placebo-Controlled Crossover Open-label, Dose Ascending X1739 CX1739 300 mg 300 mg CX1739 CX1739 Screening Baseline 600 mg 900 mg Randomize Placebo Placebo Week 1 Week 2 Week 3 Week 4 R
Slide 3: Weekly Acute Dose Testing of CX1739 vs Remifentanil: Bolus and Infusion Models of Opioid Use
Weekly Acute Dose Testing of CX1739 vs Remifentanil: Bolus and Infusion Models of Opioid Use CX1739/Placebo REMI-Bolus js 0, 300, 600, 900 mg Single, acute bolus Contras ites 3-Hr Preadministration injection M dal of ok Infusion For Cmax Model of acute overdose lodel of chronic use Single, Acute Ora
Slide 4: REMI-Infusion Protocol: A Model of Chronic Opioid Use for Pain Management
Per cent change from baseline REMI-Infusion Protocol: A Model of Chronic Opioid Use for Pain Management Effects of Remifentanil on Respiratory Rate (RR) in Representative Subject Remifentanil Bolus 0.25 ugikg mifentanil Infusion to 2 ng/ml 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 minutes
Slide 5: CX1739 Antagonizes the Respiratory Depressive Effects of Remifentanil
CX1739 Antagonizes the Respiratory Depressive Effects of Remifentanil (CX1739 Effects on Opioid Induced Respiratory Depression ‘Mean Change from Baseline
Slide 6: CX1739 is Safe and Well Tolerated with No SAEs
Adverse Events Nos CX1739 is Safe and Well Tolerated with No SAEs CX1739 is Safe: Majority of AEs Occur Post-Remifentanil Adverse Events * 38 of 48 AEs occurred after remifentanil * Pre-remifentanil Placebo had as many AEs as all doses of CX1739 combined + Most frequent AEs were nausea, vomiting, he
Slide 7: REMI-Bolus Protocol: A Model of Intravenous Opioid Overdose
Per cent change from baseline REMI-Bolus Protocol: A Model of Intravenous Opioid Overdose Effects of Remifentanil on Respiratory Rate (RRT) in Representative Subject 205 Remifentanil 10 1 ug/kg K A ao a1 12 13 /1a\ a5 7 18 19 20 21 24 25 minutes 04 Emax - maximal depression of RR 20 | ‘Tmax — time (
Slide 8: CX1739 Does Not Prevent the Initial Drop in Respiratory Depression in the IV Opioid Overdose Challenge
CX1739 Does Not Prevent the Initial Drop in Respiratory Depression In the IV Opioid Overdose Challenge Placebo 300 mg 600 mg 900 mg N=17 N=17 N=17 N=17 Emax* (%) 65.1 +/-23.0 -61.9 +/-26.7 -75.8 +/-22.6 72.6 +/-24.3 Tmax* 5.8 +1-5.1 4.5 +1-3.7 3.2 41-26 3.4 413.1 (minutes) Recovery time* i 7.6 +/-10
Slide 9: Conclusion: CX1739 Has Potential Clinical Utility for the Treatment of Opioid Induced Respiratory Depression
CX1739 Respite Conclusion: CX1739 Has Potential Clinical Utility for the Treatment of Opioid Induced Respiratory Depression » CX1739 significantly antagonized remifentani duced respiratory depression during REMI-Infusion, a model of opioid induced respiratory depression (OIRD). » CX1739 is safe and
RespireRx Pharmaceuticals — Technical Presentation (June 2017) on 6ix